XTX Topco Ltd Makes New $468,000 Investment in Calumet, Inc. $CLMT

XTX Topco Ltd bought a new stake in shares of Calumet, Inc. (NASDAQ:CLMTFree Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 29,700 shares of the oil and gas company’s stock, valued at approximately $468,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Amalgamated Bank bought a new position in shares of Calumet in the second quarter valued at approximately $37,000. University of Texas Texas AM Investment Management Co. lifted its stake in Calumet by 109.4% in the 2nd quarter. University of Texas Texas AM Investment Management Co. now owns 3,350 shares of the oil and gas company’s stock worth $53,000 after purchasing an additional 1,750 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in Calumet in the 2nd quarter valued at $111,000. Premier Path Wealth Partners LLC grew its position in shares of Calumet by 11.4% during the 2nd quarter. Premier Path Wealth Partners LLC now owns 12,853 shares of the oil and gas company’s stock valued at $202,000 after purchasing an additional 1,320 shares in the last quarter. Finally, SP Asset Management LLC purchased a new position in shares of Calumet during the 2nd quarter valued at $205,000. 34.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CLMT has been the subject of several research analyst reports. TD Cowen lifted their price objective on Calumet from $15.00 to $18.00 and gave the company a “hold” rating in a research note on Tuesday, November 11th. Zacks Research raised Calumet from a “strong sell” rating to a “hold” rating in a report on Thursday, November 6th. HC Wainwright reissued a “buy” rating and set a $33.00 price objective on shares of Calumet in a report on Monday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Calumet in a research note on Monday. Finally, The Goldman Sachs Group lifted their target price on shares of Calumet from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, October 22nd. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.04.

Get Our Latest Analysis on CLMT

Calumet Stock Performance

CLMT stock opened at $19.45 on Friday. The company has a market capitalization of $1.69 billion, a PE ratio of -45.23 and a beta of 1.18. Calumet, Inc. has a one year low of $7.68 and a one year high of $23.75. The company’s 50 day moving average price is $18.98 and its two-hundred day moving average price is $16.90.

Calumet (NASDAQ:CLMTGet Free Report) last announced its quarterly earnings data on Friday, November 7th. The oil and gas company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.09. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Calumet’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same period last year, the company posted ($1.18) EPS. On average, research analysts predict that Calumet, Inc. will post -3.02 EPS for the current year.

About Calumet

(Free Report)

Calumet, Inc engages in the manufacturing, formulating, and marketing of a diversified slate of specialty branded products and renewable fuels to customers across a broad range of consumer-facing and industrial markets. It operates through the following segments: Specialty Products & Solutions, Performance Brands, Montana/Renewables, and Corporate.

See Also

Institutional Ownership by Quarter for Calumet (NASDAQ:CLMT)

Receive News & Ratings for Calumet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calumet and related companies with MarketBeat.com's FREE daily email newsletter.